Table 1.
Baseline Characteristics of Pediatric HSCT Recipients (n=140), Overall and By CMV Serostatus of Donor/Recipient.
| Overall N=140 N (%) |
D−/R− Graft N=35 N (%) |
Other Graft N=105 N (%) |
|
|---|---|---|---|
| Male | 78 (55.7) | 20 (57.1) | 58 (55.2) |
| Diagnosis | |||
| ALL | 81 (57.9) | 18 (51.4) | 63 (60.0) |
| AML | 54 (38.6) | 16 (45.7) | 38 (36.2) |
| MDS | 5 (3.6) | 1 (2.9) | 4 (3.8) |
| Disease Stage | |||
| Early | 49 (35.0) | 14 (40.0) | 35 (33.3) |
| Intermediate | 81 (57.9) | 19 (54.3) | 62 (59.1) |
| Advanced | 10 (7.1) | 2 (5.7) | 8 (7.6) |
| Ethnicity | |||
| Hispanic White | 65 (46.4) | 11 (31.4) | 54 (51.4) |
| Non-Hispanic White | 56 (40.0) | 20 (57.1) | 36 (34.3) |
| Asian | 13 (9.3) | 2 (5.7) | 11 (10.5) |
| African-American | 6 (4.3) | 2 (5.7) | 4 (3.8) |
| Donor Type | |||
| Sibling | 78 (55.7) | 23 (65.7) | 55 (52.4) |
| Unrelated | 62 (44.3) | 12 (34.3) | 50 (47.6) |
| Donor Age | |||
| 0–19 Years | 74 (52.9) | 23 (65.7) | 51 (48.6) |
| 20–39 Years | 43 (30.7) | 8 (22.9) | 35 (33.3) |
| 40–55 Years | 23 (16.4) | 4 (11.4) | 19 (18.1) |
| Graft Source | |||
| Bone Marrow | 77 (55.0) | 18 (51.4) | 59 (56.2) |
| Peripheral Blood | 63 (45.0) | 17 (48.6) | 46 (43.8) |
| Year of Transplantation | |||
| 1997–2002 | 69 (49.3) | 18 (51.4) | 51 (48.6) |
| 2003–2007 | 71 (50.7) | 17 (48.6) | 54 (51.4) |
| Female-to-Male Graft | |||
| Yes | 32 (22.9) | 8 (22.9) | 24 (22.9) |
| No | 108 (77.1) | 27 (77.1) | 81 (77.1) |
| Conditioning Regimen | |||
| *Total Body Irradiation + Etoposide | 74 (52.9) | 17 (48.6) | 57 (54.3) |
| *Total Body Irradiation + †CTX(±other) | 45 (32.1) | 12 (34.3) | 33 (31.4) |
| Busulfan + †CTX | 21 (15.0) | 6 (17.1) | 15 (14.3) |
| GVHD Prophylaxis | |||
| Cyclosporin + Methotrexate(±other) | 81 (57.9) | 24 (68.6) | 57 (54.3) |
| Tacrolimus(±other) | 51 (36.4) | 11 (31.4) | 40 (38.1) |
| Cyclosporin±Mycophenolate Mofetil | 8 (5.7) | 0 | 8 (7.6) |
*
Irradiation was delivered in fractionated doses in 116/119 cases.
†
Cyclophosphamide